Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 4, 2025Open Access

Success Rates and Timelines of African-Inclusive Phase III Trials: A Retrospective Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJoab Williamson

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals 69.6% success rates in Phase III trials with African sites, suggesting improved global relevance for clinical trial data.

Key Points

  • Overall, 69.6% of Phase III trials with African sites achieved positive primary endpoints.
  • Non-oncology trials showed a higher success rate of 73.5%, compared to 55.9% for oncology trials.
  • Mean trial duration was shorter at 1,085 days, compared to the typical global duration of around 1,200 days.
  • Including African sites in trials could enhance diversity and relevance of clinical data for broader populations.

Cite This Study

Joab Williamson (2025) studied this question.

synapsesocial.com/papers/689a0f8de6551bb0af8d0f5dhttps://doi.org/10.20944/preprints202506.0876.v2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Trial characteristics and results reporting among oncology clinical trials involving African countries.2026
  2. 2The landscape of oncology clinical trials in Africa over the last three decades (1995-2025).2026
  3. 3Tumor‐Specific Success Probabilities and Factors Associated With Phase <scp>III</scp> Trials in Oncology Drug Development2026
  4. 4Phase III Trials in India: A Comprehensive Analysis of the Clinical Trials Registry-India2026
  5. 5Global Landscape of Phase III Interventional Clinical Trials in Colorectal Cancer2024